Zynerba ’s Phase II epilepsy trial of ZYN002 fails to meet primary endpoint

Zynerba Pharmaceuticals has reported top-line results from the Phase II STAR 1 clinical trial of ZYN002 to treat adult epilepsy patients with focal seizures.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news